{"id":514,"date":"2026-04-12T11:32:08","date_gmt":"2026-04-12T11:32:08","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=514"},"modified":"2026-08-30T03:53:24","modified_gmt":"2026-08-30T03:53:24","slug":"lucitrelag-trelagliptin-100-mgx20-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/pt\/product\/lucitrelag-trelagliptin-100-mgx20-tablets\/","title":{"rendered":"LuciTrelag"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n

These highlights do not include all the information needed to use LuciTrelag safely and effectively. See full prescribing information for LuciTrelag.<\/strong><\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LuciTrelag is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION <\/strong><\/strong><\/span><\/p>\n

Usually, for adults, 100 mg of trelagliptin is orally administered once a week. The score line is not intended for dose adjustment. Do not break or crush the tablet.<\/span><\/p>\n

 <\/span><\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS <\/strong><\/strong><\/span><\/p>\n

Tablets: 100 mg\u00d720 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS <\/strong><\/strong><\/span><\/p>\n

Hypersensitivity to trelagliptin or any of its components.<\/span><\/p>\n

Patients with severe renal impairment or end-stage renal failure on dialysis.<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS <\/strong><\/strong><\/span><\/p>\n

Hypoglycemia<\/strong><\/strong><\/span><\/p>\n

The risk of hypoglycemia may increase with concomitant use of trelagliptin and sulfonylureas or insulin preparations. Therefore, reduction of the dosage of sulfonylureas or insulin preparations should be considered to reduce the risk of hypoglycemia when used in combination with trelagliptin.<\/span><\/p>\n

 <\/span><\/p>\n

Acute Pancreatitis<\/strong><\/strong><\/span><\/p>\n

Postmarketing events of acute pancreatitis have been reported for trelagliptin and have been associated with other DPP-4 inhibitors. After initiation of trelagliptin, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, trelagliptin should be promptly discontinued and appropriate management should be initiated.<\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS <\/strong><\/strong><\/span><\/p>\n

Table 1. Adverse drug reactions with trelagliptin in clinical studies<\/span><\/p>\n

 <\/span><\/p>\n\n\n\n\n\n\n\n
\n

<\/span><\/p>\n<\/td>\n

\n

\u2265 0.1% to < 5%<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Hypersensitivity<\/span><\/p>\n<\/td>\n

\n

Rash<\/span><\/p>\n

Pruritus<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Cardiovascular<\/span><\/p>\n<\/td>\n

\n

Atrial fibrillation<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

 <\/span><\/p>\n

 <\/span><\/p>\n

Hepatic<\/span><\/p>\n<\/td>\n

\n

ALT increased<\/span><\/p>\n

AST increased<\/span><\/p>\n

\u03b3-GTP increased<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

 <\/span><\/p>\n

Others<\/span><\/p>\n<\/td>\n

\n

Lipase increased<\/span><\/p>\n

Amylase increased CPK increased<\/span><\/p>\n

Urinary occult blood positive<\/span><\/p>\n

Nasopharyngitis<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/span><\/p>\n

DRUG INTERACTIONS <\/strong><\/strong><\/span><\/p>\n

No clinically meaningful interactions (with both drug and food) were observed, and no need for <\/span><\/p>\n

dose adjustment of trelagliptin or other concomitantly administered drugs was identified.<\/span><\/p>\n

Trelagliptin is primarily renally excreted. Cytochrome (CYP) P450-related metabolism is <\/span><\/p>\n

negligible. No significant drug-drug interactions were observed with the CYP-substrates tested.<\/span><\/p>\n

 <\/span><\/p>\n

Effects of other medicinal products on trelagliptin<\/span><\/p>\n

Results from clinical interaction studies demonstrate that there are no clinically relevant effects of <\/span><\/p>\n

glimepiride or metformin on the pharmacokinetics of trelagliptin.<\/span><\/p>\n

 <\/span><\/p>\n

Effects of trelagliptin on other medical products<\/span><\/p>\n

In vitro studies suggest that trelagliptin does not inhibit nor induce CYP 450 isoforms at <\/span><\/p>\n

concentrations achieved with the recommended dose of 100 mg trelagliptin (see section 5.2).<\/span><\/p>\n

Trelagliptin is a substrate of P-glycoprotein and in vitro studies showed slight inhibition of transport <\/span><\/p>\n

of digoxin through P-glycoprotein (IC50 value : 500 \u00b5mol\/L or higher) or showed inhibition of <\/span><\/p>\n

uptake of metformin, an organic cationic transporter-2 (OCT2) substrate (IC50 value : 55.9 <\/span><\/p>\n

\u00b5mol\/L).<\/span><\/p>\n

In clinical studies, trelagliptin had no clinically relevant effect on the pharmacokinetics of caffeine, <\/span><\/p>\n

tolbutamide, dextromethorphan, midazolam, metformin, or glimepiride, thus providing in vivo <\/span><\/p>\n

evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP2C9, CYP2D6, <\/span><\/p>\n

CYP3A4 or OCT2.<\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS <\/strong><\/strong><\/span><\/p>\n

Pregnancy<\/span><\/p>\n

Trelagliptin should not be administered to women who are or may be pregnant, unless the <\/span><\/p>\n

expected therapeutic benefit is thought to outweigh any possible risk to the mother and the fetus.<\/span><\/p>\n

 <\/span><\/p>\n

Lactation<\/span><\/p>\n

During the treatment with trelagliptin, nursing should be avoided if the administration of this <\/span><\/p>\n

drug is necessary for the mother.<\/span><\/p>\n

 <\/span><\/p>\n

Storage <\/strong><\/strong><\/span><\/p>\n

Store at 20\u2103 to 25\u2103 (68\u2109 to 77\u2109), excursions permitted between 15\u2103 and 30\u2103 (59\u2109 and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciTrelag is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.<\/p>","protected":false},"featured_media":1876,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[52],"product_tag":[],"class_list":["post-514","product","type-product","status-publish","has-post-thumbnail","product_cat-diabetes","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product\/514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/comments?post=514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media\/1876"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media?parent=514"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_brand?post=514"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_cat?post=514"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_tag?post=514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}